Loading
Neoplasm Staging / Lymphoma, Large B Cell, Diffuse / Early Therapeutic Adjustment · Journal article
Annals of Medicine · July 22, 2026
Encouraging direction, but not yet definitive.
This retrospective cohort study of 32 previously untreated CD5-positive DLBCL patients demonstrates high response rates (ORR 100% after 3 cycles, CRR 71.9%) and 2-year survival rates (PFS 70%, OS 82.7%) with first-line Pola-R-CHP. Failure to achieve complete response after interim PET/CT (3 cycles) was a significant predictor of inferior progression-free and overall survival (PFS HR 18.1, p=0.02; OS HR 12.3, p=0.033), suggesting interim response guides prognosis in this high-risk population.
Multicenter, retrospective cohort study. Previously untreated CD5-positive DLBCL patients enrolled between April 2023 and February 2025; median age 63.5 years; 78.1% stage III-IV; 59.4% IPI score ≥3.. Intervention: Pola-R-CHP (polatuzumab vedotin combined with rituximab, cyclophosphamide, doxorubicin, and prednisone) as first-line therapy.. n = 32. Multicenter study; specific countries/regions not specified in source text..
Overall response rate 100% after 3 cycles with complete response rate 71.9% At end of treatment, ORR 93.8% and CRR 75% 2-year progression-free survival 70% and overall survival 82.7% after median follow-up 17.9 months
Grade 3-4 adverse events in 31.3% of patients, with neutropenia most common
For clinicians treating CD5+ DLBCL with Pola-R-CHP, interim PET/CT response after 3 cycles appears prognostically informative; failure to achieve complete response at this timepoint predicts substantially worse survival outcomes and may warrant consideration of treatment modification strategies. The high 2-year survival rates suggest Pola-R-CHP is effective for this historically poor-prognosis subtype, though confirmation in larger prospective studies is needed.
Retrospective multicenter study showing high response rates and 2-year survival outcomes for a high-risk CD5+ DLBCL population treated with Pola-R-CHP, with interim PET response predicting survival, but limited by small sample size, retrospective design, and short median follow-up.
As stated by the source record.
Quoted from the source exactly as published.
For clinicians treating CD5+ DLBCL with Pola-R-CHP, interim PET/CT response after 3 cycles appears prognostically informative; failure to achieve complete response at this timepoint predicts substantially worse survival outcomes and may warrant consideration of treatment modification strategies. The high 2-year survival rates suggest Pola-R-CHP is effective for this historically poor-prognosis subtype, though confirmation in larger prospective studies is needed.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background. CD5-positive diffuse large B-cell lymphoma (DLBCL) is an aggressive subtype with poor outcomes. Following the approval of Pola-R-CHP in China, this study aimed to evaluate its efficacy as initial therapy for this high-risk population.Methods. We conducted a multicenter, retrospective study of previously untreated CD5-positive DLBCL patients who received Pola-R-CHP as first-line therapy between April 2023 and February 2025. Treatment response was assessed by PET/CT after 3 cycles and at the end of treatment.Results. Among 32 enrolled patients (median age 63.5 years), 78.1% had stage III-IV disease and 59.4% had an International Prognostic Index score ≥3. The overall response rate (ORR) was 100% after 3 cycles, with a complete response rate (CRR) of 71.9%. At end of treatment, the ORR and CRR were 93.8% and 75%, respectively. After a median follow-up of 17.9 months, 2-year progression-free survival (PFS) and overall survival rates (OS) were 70% and 82.7%. After adjusting covariates, failure to achieve a complete response (CR) after 3 cycles was a predictor of inferior survival [PFS HR: 18.1, p = 0.02; OS HR: 12.3, p = 0.033]. Grade 3-4 adverse events occurred in 31.3% of patients, with neutropenia being most common.Conclusions. CD5-positive DLBCL patients exhibited rapid and promising responses to first-line Pola-R-CHP with an acceptable safety profile. Interim response assessment is a potential prognostic factor. In instances where CR is not attained by the interim PET/CT, it is advisable to consider treatment modification, as this may indicate a potential failure to achieve CR.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.